scholarly journals Induced Apoptosis Investigation in Wild-type and FLT3-ITD Acute Myeloid Leukemia Cells by Nanochannel Electroporation and Single-cell qRT-PCR

2016 ◽  
Vol 24 (5) ◽  
pp. 956-964 ◽  
Author(s):  
Keliang Gao ◽  
Xiaomeng Huang ◽  
Chi-Ling Chiang ◽  
Xinmei Wang ◽  
Lingqian Chang ◽  
...  
BIOPHYSICS ◽  
2015 ◽  
Vol 60 (6) ◽  
pp. 953-956 ◽  
Author(s):  
R. S. Fadeev ◽  
M. E. Solovieva ◽  
D. A. Slyadovskiy ◽  
S. G. Zakharov ◽  
I. S. Fadeeva ◽  
...  

2019 ◽  
Vol 10 (27) ◽  
pp. 6767-6778 ◽  
Author(s):  
Jie Xiong ◽  
Xingyi Kuang ◽  
Tingting Lu ◽  
Xu Liu ◽  
Bingqing Cheng ◽  
...  

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4229-4229
Author(s):  
Michela Aluigi ◽  
Antonio Curti ◽  
Emanuela Ottaviani ◽  
Giovanna Lucchetti ◽  
Valentina Salvestrini ◽  
...  

Abstract The expression of the catalytic enzyme of tryptophan, indoleamine 2,3 dioxygenase (IDO) has been identified as a T-cell inhibitor effector pathway in different normal and neoplastic cells. We have recently shown that normal bone marrow (BM) cells, including hematopoietic CD34+ cells, express IDO mRNA only upon IFN-γ stimulation, whereas in a subset of human acute myeloid leukemia cells (AML) IDO is constitutively expressed both at molecular and protein level and induces immunological escape by promoting the generation of T-reg cells. To investigate whether the IDO transcript can be used as a marker for minimal residual disease (MRD) detection, we used a sensitive real-time reverse transcription-polymerase reaction assay (qRT-PCR) to quantify IDO mRNA levels in peripheral blood (PB) and BM samples of newly diagnosed AML patients. The level of IDO transcript was evaluated as IDO copy number/104 ABL copies. As control samples, we used normal PB and BM mononuclear cells (MNCs). Our data showed that normal BM and PB cells expressed minimal amount of IDO mRNA (range 100–1000). Among AML samples, we identified three subsets of patients according to IDO mRNA expression: 1) 33/74 (44.6%) IDO negative (i.e. range < 100), 28/74 (37.84%) IDO low (range 100–1000) and 13/74 (17.6%) IDO high (i.e. range > 1000). BM and PB AML blasts gave similar results. Assessment of protein expression and enzymatic activity was in accordance with molecular results. Some patients were evaluated for IDO mRNA expression before and after induction chemotherapy and the IDO levels were found to correlate with the reduction of BM blasts. Taken together, our qRT-PCR data demonstrate that normal PB and BM cells are negative for IDO mRNA expression, which, in turn, is significantly up-regulated in a subset of AML patients (IDO high) and IDO mRNA expression correlates with tumor burden, thus suggesting its possible role in the detection of MRD in IDO high patients.


2021 ◽  
pp. 105207
Author(s):  
Catarina Sofia Mateus Reis e Silva ◽  
Paola Cristina Branco ◽  
Keli Lima ◽  
Fabiana Lima Silva ◽  
Paulo Roberto Hrihorowitsch Moreno ◽  
...  

Biomolecules ◽  
2019 ◽  
Vol 9 (9) ◽  
pp. 505
Author(s):  
Minjing Li ◽  
Shiyu Hao ◽  
Chunling Li ◽  
Huimin Xiao ◽  
Liyuan Sun ◽  
...  

Current strategies are not especially successful in the treatment of acute myeloid leukemia (AML). The identification and characterization of oncogenes crucial to the survival and growth of leukemia cells will provide potential targets for the exploitation of novel therapies. Herein, we report that the elevated expression of SH3 domain-binding protein 5 (SH3BP5) significantly correlates with poor outcomes of AML patients. To test whether SH3BP5 contributes to the growth and survival of AML cells, we use the shRNA-encoding lentivirus system to achieve the knockdown of SH3BP5 expression in human AML cell lines U937, THP-1, Kasumi-1, and MV4-11. Functionally, the knockdown of SH3BP5 expression markedly inhibits the cell viability and induced apoptosis of these leukemia cells. Mechanistically, western blot analysis indicates that the knockdown of SH3BP5 expression decreases the phosphorylation of JNK and BAD. Moreover, the JNK agonist anisomycin rescues the growth inhibition phenotype of SH3BP5 deficiency in THP-1 cells. Moreover, the expression of SH3BP5 positively correlates with CD25 and CD123 levels. Finally, our study highlights the crucial role of SH3BP5 in promoting the survival of AML cells, and its suppression may be a potential therapeutic strategy for treating human AML.


Sign in / Sign up

Export Citation Format

Share Document